UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

Journal of viral hepatitis, 2010-01, Vol.17 (1), p.16-22

2010

Volltextzugriff (PDF)

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

Journal of viral hepatitis, 2009-11, Vol.16 (11), p.784-789

2009

Volltextzugriff (PDF)

UV-cured FRP joint thickness effect on coupled composite pipes

Composite structures, 2007-09, Vol.80 (2), p.290-297

2007

Volltextzugriff (PDF)

Reversing the Curse: Agricultural Millennialism at the Illinois Industrial University

Church history, 2004-12, Vol.73 (4), p.759-791

Smith, Brett H.

2004

Volltextzugriff (PDF)

[518] EFFICACY OF ENTECAVIR AND LAMIVUDINE IN CHRONIC HEPATITIS B PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS

Journal of hepatology, 2007, Vol.46, p.S197-S197

2007

Volltextzugriff (PDF)

20 ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTS

Journal of hepatology, 2009, Vol.50, p.S10-S10

2009

Volltextzugriff (PDF)

Reversing the Curse: Agricultural Millennialism at the Illinois Industrial University1

Church history, 2004-12, Vol.73 (4), p.759-791

Smith, Brett H.

2004

Volltextzugriff (PDF)

Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman’s Disease

Journal of Virology, 1999-05, Vol.73 (5), p.4181-4187

1999

Volltextzugriff (PDF)

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy

AIDS (London), 2008-09, Vol.22 (14), p.1779-1787

2008

Volltextzugriff (PDF)

Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia

The Journal of infectious diseases, 1996-05, Vol.173 (5), p.1252-1255

1996

Volltextzugriff (PDF)

A Place Somewhat Apart: The Private Worlds of a Late Nineteenth-Century Public University - By Philip Harrold. Princeton Theological Monograph Series 63. Eugene, Ore.: Pickwick, 2006. xii + 243 pp. $26.00 paper

Church history, 2007-09, Vol.76 (3), p.661-662

Smith, Brett H.

2007

Volltextzugriff (PDF)

Cytomegalovirus as a Primary Pulmonary Pathogen in AIDS

Chest, 1997-01, Vol.111 (1), p.128-134

1997

Volltextzugriff (PDF)

PMC39 USING MIXED TREATMENT COMPARISON MODELING TO COMPARE PROPORTIONS OF NAIVE HBEAG(+) CHB PATIENTS WHO ACHIEVED UNDETECTABLE HBV DNA

Value in health, 2009, Vol.12 (7), p.A394-A394

2009

Volltextzugriff (PDF)

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naÃ¯ve HBeAg-positive patients with chronic hepatitis B: Loss of HBsAg antigen with entecavir

Journal of viral hepatitis, 2010-01, Vol.17 (1), p.16-22

2010

Volltextzugriff (PDF)

Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B

Journal of clinical virology, 2006-01, Vol.36, p.S87-S87

2006

Volltextzugriff (PDF)

P.086 Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B

Journal of clinical virology, 2006, Vol.36, p.S87-S87

2006

Volltextzugriff (PDF)

513 Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection: Results of three pivotal trials

Journal of hepatology, 2006-04, Vol.44, p.S191-S191

2006

Volltextzugriff (PDF)

HIV as a chronic disease: implications for long-term care at an AIDS-dedicated skilled nursing facility

Journal of urban health, 2000-06, Vol.77 (2), p.187-203

2000

Volltextzugriff (PDF)

80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

Journal of hepatology, 2006-04, Vol.44, p.S36-S36

2006

Volltextzugriff (PDF)

A Place Somewhat Apart: The Private Worlds of a Late Nineteenth-Century Public University

Church History, 2007, Vol.76 (3), p.661-662

Smith, Brett H.

2007

Volltextzugriff (PDF)

512 Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B

Journal of hepatology, 2006-04, Vol.44, p.S190-S191

2006

Volltextzugriff (PDF)

45 Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (study ETV-027)

Journal of hepatology, 2006-04, Vol.44, p.S21-S22

2006

Volltextzugriff (PDF)

P.090 Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)

Journal of clinical virology, 2006, Vol.36, p.S89-S89

2006

Volltextzugriff (PDF)

Shakespeare's England. An Account of the Life and Manners of His Age

The Modern Language Review, 1917, Vol.12 (2), p.216-217

H. F. B. Brett-Smith

1917

Volltextzugriff (PDF)

Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)

Journal of clinical virology, 2006-01, Vol.36, p.S86-S86

2006

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(93)

Publikationsform

Sprache

Englisch
(97)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

UV-cured FRP joint thickness effect on coupled composite pipes

Reversing the Curse: Agricultural Millennialism at the Illinois Industrial University

[518] EFFICACY OF ENTECAVIR AND LAMIVUDINE IN CHRONIC HEPATITIS B PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS

20 ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTS

Reversing the Curse: Agricultural Millennialism at the Illinois Industrial University1

Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman’s Disease

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy

Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia

A Place Somewhat Apart: The Private Worlds of a Late Nineteenth-Century Public University - By Philip Harrold. Princeton Theological Monograph Series 63. Eugene, Ore.: Pickwick, 2006. xii + 243 pp. $26.00 paper

Cytomegalovirus as a Primary Pulmonary Pathogen in AIDS

PMC39 USING MIXED TREATMENT COMPARISON MODELING TO COMPARE PROPORTIONS OF NAIVE HBEAG(+) CHB PATIENTS WHO ACHIEVED UNDETECTABLE HBV DNA

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naÃ¯ve HBeAg-positive patients with chronic hepatitis B: Loss of HBsAg antigen with entecavir

Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B

P.086 Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B

513 Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection: Results of three pivotal trials

HIV as a chronic disease: implications for long-term care at an AIDS-dedicated skilled nursing facility

80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

A Place Somewhat Apart: The Private Worlds of a Late Nineteenth-Century Public University

512 Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B

45 Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (study ETV-027)

P.090 Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)

Shakespeare's England. An Account of the Life and Manners of His Age

Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)

Suchergebnisse filtern